Back to Dashboard
RXST · Healthcare

RXSIGHT INC

USA Healthcare Filing: 2025-12-31
Smart-money confidence · 1 of 3 sources firing
Weak — few signals

No standout activity across the feeds we track.

Hedge funds
38
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
◆ Next steps Interested in RXSIGHT INC? Here's what to do with it.
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$233M
Industry
Medical Devices
Sector
Healthcare
Exchange
NasdaqGM
About RXSIGHT INC

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity;…

Who's behind the signal
Every informed buyer we can see on RXST, across all three feeds.
Hedge funds · 7
Point72 (Steve Cohen) Increased +693%
D.E. Shaw & Co Increased +3%
AQR Capital Management Increased +281%
+1 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar. RXSIGHT INC isn't in the top-10 model right now, but 7 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
7
Investors
1
New positions
3
Increasing
2
Decreasing
1
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
New position
% of portfolio
0.0%
Position change
NEW
0.0% of Tudor Investment's portfolio
Trust weight: 1.1×
Increased +693%
% of portfolio
0.0%
Position change
+693%
0.0% of Point72's portfolio
Trust weight: 1.0×
Increased +3%
% of portfolio
0.0%
Position change
+3%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
Increased +281%
% of portfolio
0.0%
Position change
+281%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
Decreased −3%
% of portfolio
0.0%
Position change
−3%
0.0% of Millennium Management's portfolio
Trust weight: 1.4×
Unchanged
% of portfolio
0.0%
Position change
0.0% of Baillie Gifford & Co's portfolio
Trust weight: 1.0×
Decreased −19%
% of portfolio
0.0%
Position change
−19%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to RXSIGHT INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell RXSIGHT INC or any security.

Get the Weekly Update

Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime